Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein
Sign Up to like & getrecommendations! Published in 2017 at "Protoplasma"
DOI: 10.1007/s00709-017-1129-5
Abstract: The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating critical biochemical pathways continues to emerge. The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated… read more here.
Keywords: disease biomarkers; disease; potential disease; activation protein ... See more keywords
Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14030
Abstract: Alzheimer's disease (AD) is associated with neurodegenerative changes resulting clinically in progressive cognitive and functional deficits. The only therapies are the cholinesterase inhibitors donepezil, galantamine and rivastigmine and the N‐methyl‐D‐aspartate‐receptor antagonist memantine. Donepezil acts primarily… read more here.
Keywords: donepezil; beyond symptomatic; alzheimer disease; treatment ... See more keywords
Riociguat in systemic sclerosis: a potential for disease modification.
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the rheumatic diseases"
DOI: 10.1136/annrheumdis-2020-218180
Abstract: We read with great interest the results of the recently published Riociguat Safety and Efficacy in Systemic Sclerosis (RISE-SSc) trial1 and believe that additional analyses could further elucidate the role of riociguat in systemic sclerosis… read more here.
Keywords: sclerosis; disease modification; sclerosis potential; riociguat systemic ... See more keywords